Crestline Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Crestline Management’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-158,659	Closed	-$79K	–	296
2022 Q2	$79K	Sell	158,659 -2,055	-1%	-$995	0.01%	213
2022 Q1	$98K	Buy	+160,714	New	+$84.2K	0.01%	245

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Crestline Management's MTCR Position: Q3 2022 in Review

Crestline Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q3 2022, closing a stake of 158,659 shares — an estimated $79K sold.

Crestline Management first reported a position in MTCR in Q1 2022 and held it in 2 quarters. The position peaked at $98K in Q1 2022. 27 funds tracked by Wall St. Rank hold MTCR as of Q3 2022.

Crestline Management reported no remaining Metacrine, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Crestline Management sold 158,659 Metacrine, Inc. Common Stock shares in Q3 2022, an estimated $79K.
Crestline Management first reported a position in Metacrine, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Crestline Management's Metacrine, Inc. Common Stock position peaked at $98K in Q1 2022.
27 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.